Figitumumab

Figitumumab (previously CP-751871) is a monoclonal antibody targeting the insulin-like growth factor-1 receptor being investigated for the treatment of various types of cancer, for example adrenocortical carcinoma and non-small cell lung cancer (NSCLC).

This drug is being developed by Pfizer.

Anti-cancer mechanism
See Insulin-like growth factor 1 receptor role in cancer.

Clinical trials
The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths but others continue.

It will be included in the forthcoming I-SPY2 breast cancer trial.